Core Insights - Amarin Corporation will present new data on icosapent ethyl (IPE) at the European Society of Cardiology (ESC) Congress 2025, highlighting its cardioprotective effects [1][2] - The data will focus on IPE's role in reducing cardiovascular risk through various mechanisms, including inflammation and lipoprotein oxidation [2][3] Presentation Highlights - New analyses from the REDUCE-IT trial will evaluate the clinical benefits of IPE, including its impact on hospitalization risk and duration [2][3] - Mechanistic studies will explore the effects of eicosapentaenoic acid (EPA) on inflammasome activation and pro-inflammatory protein expression in endothelial cells [2][3] Educational Initiatives - Amarin will support educational programming addressing residual cardiovascular risk, featuring presentations by medical and scientific leaders in Europe [3][5] Symposium and Abstracts - Moderated poster presentations will include topics such as the reduction of cardiovascular disease risk in cardiovascular-kidney-metabolic syndrome and the impact of IPE across different apolipoprotein B and triglyceride levels [4][7] - Oral presentations will cover the effects of IPE on hospitalization risks and the modulation of inflammasome activation in macrophages [7] Company Overview - Amarin is focused on advancing cardiovascular disease management and understanding residual cardiovascular risk beyond traditional therapies [8] - The company has a global presence with offices in the United States, Ireland, Switzerland, and partnerships worldwide [8] Product Information - VASCEPA (icosapent ethyl) is the first FDA-approved treatment solely comprising IPE, aimed at high-risk patients with persistent cardiovascular risk despite statin therapy [9] - Since its launch, VASCEPA has been prescribed over 25 million times and is covered by most major medical insurance plans [9]

Core Insights - Amarin Corporation has established a partnership with Recordati to enhance the commercialization of VAZKEPA in Europe, which is expected to significantly increase shareholder value [2][4] - The company has initiated a global restructuring plan aimed at achieving $70 million in operating expense savings over the next 12 months [5] - Financial results for Q2 2025 show an 8% increase in total net revenue compared to Q2 2024, primarily driven by licensing and royalty revenue from the European partnership [6][9] Recent Strategic Actions - The exclusive long-term license and supply agreement with Recordati covers 59 countries in Europe, aiming to accelerate VAZKEPA's market adoption [4] - The partnership is expected to facilitate a smooth commercial transition, largely completed by the end of 2025 [4] Global Restructuring - The restructuring is a direct response to the partnership with Recordati, focusing on reducing operating expenses and right-sizing the company's operations [5] - Most of the anticipated savings will come from eliminating commercial roles in European operations [5] Q2 2025 Financial Highlights - Total net revenue for Q2 2025 was $72.7 million, an increase of $5.3 million or 8% from Q2 2024 [6][9] - Operating expenses were $43.6 million, slightly up from $43.3 million in Q2 2024, with a significant restructuring charge of $22.8 million included [6][12] - The company reported a net loss of $14.1 million for Q2 2025, compared to a net income of $1.5 million in Q2 2024 [16] Revenue Breakdown - U.S. product revenue decreased by 17% to $36.5 million, while European revenue increased by 85% to $6.6 million [8] - Licensing and royalty revenue rose by 31% to $26.1 million, primarily due to the upfront payment from the Recordati agreement [9] Cash Position - As of the end of Q2 2025, Amarin reported nearly $300 million in cash and no debt, positioning the company well for future growth [3][16]

Core Points - Amarin Corporation has entered into a long-term licensing and supply agreement with Recordati S.p.A. to commercialize VAZKEPA in 59 countries, primarily in Europe, aiming to enhance the product's market reach and financial position [1][2] - The partnership is expected to generate approximately $70 million in cost savings over the next 12 months through streamlined global operations, particularly by reducing commercialization expenses in Europe [1][12] - Amarin's financial strength includes nearly $300 million in cash and no debt, positioning the company for accelerated positive cash flow [2][3] Company Strategy - The collaboration with Recordati is seen as a strategic move to leverage their expertise in the cardiovascular space, which aligns with Amarin's goal of maximizing long-term shareholder value [2][4] - Amarin will continue to focus on its U.S. operations, which are profitable and provide meaningful cash flows, while also exploring international partnerships to enhance revenue generation [12] Financial Terms of the Agreement - Amarin will receive an upfront payment of $25 million and potential milestone payments up to $150 million based on Recordati's commercial sales performance [5] - The agreement includes supply-based revenues and royalties from the commercialization of VAZKEPA [5] Market Context - Recordati is a well-established pharmaceutical company with a strong presence in the cardiovascular market, which constitutes about 25% of its Specialty and Primary Care business [3] - The partnership is expected to enhance the commercial opportunity for VAZKEPA in Europe, where Amarin holds patent protection until 2039 [2][4]

Core Insights - Amarin Corporation reported a 26% decrease in total net revenue for Q1 2025, amounting to $42.0 million compared to $56.5 million in Q1 2024, primarily due to lower net selling prices and reduced volume amid U.S. generic competition [6][8][19] - The company continues to focus on maximizing the global value of its products VASCEPA and VAZKEPA, with strategic initiatives aimed at enhancing revenue streams and managing operating expenses [2][3] - Amarin regained compliance with Nasdaq listing standards following a 1-for-20 ADS ratio change, which was completed on April 11, 2025 [13][14] Financial Performance - Total net revenue for Q1 2025 was $42.0 million, a decrease of 26% from $56.5 million in Q1 2024 [6] - Net product revenue for Q1 2025 was $41.0 million, down from $55.2 million in the same period of 2024 [6][19] - Operating expenses decreased by 8% to $41.9 million in Q1 2025 from $45.5 million in Q1 2024 [6][10] - The company reported a net loss of $15.7 million for Q1 2025, compared to a net loss of $10.0 million in Q1 2024 [11][32] Market Performance - In the U.S., the company generated $35.7 million from branded VASCEPA, despite competition from generics [7][19] - In Europe, VAZKEPA's in-market demand grew 16% sequentially quarter over quarter, with significant contributions from Spain, the UK, and Central Eastern European markets [7] - In Italy, patient access was secured in 14 of 21 regions, representing over 85% of the eligible population [7] - In China, the partner Edding is advancing commercialization efforts, targeting top private hospitals and planning for National Reimbursement Drug Listing submission in 2026 [7] Strategic Initiatives - The company is focused on capitalizing on opportunities in Europe and efficiently generating revenue in the U.S. and Rest of World markets while managing operating expenses [2][3] - Amarin is preparing to introduce an authorized generic version of VASCEPA when advantageous [7] - The company continues to evaluate opportunities to expand the impact of VASCEPA/VAZKEPA in addressing cardiovascular risk globally [2][3]

Core Points - Amarin Corporation has regained compliance with Nasdaq's continued listing standards for minimum share price, confirming an average closing share price of at least $1.00 over the last 10 consecutive business days as of April 28, 2025 [2][3] - The company is now fully compliant with all Nasdaq listing requirements and will continue to be listed and traded on the Nasdaq Capital Market [3] - Amarin's focus remains on maximizing the global value of its products VASCEPA and VAZKEPA for patients [3] Company Overview - Amarin is an innovative pharmaceutical company specializing in cardiovascular disease management, with offices in Bridgewater, New Jersey, Dublin, Ireland, and Zug, Switzerland, among other locations [3] - The company is committed to enhancing the scientific understanding of cardiovascular risk that persists beyond traditional therapies and advancing treatment options [3]